Estrogen's effects in chronic autoimmune/inflammatory diseases and progression to cancer

Expert Review of Clinical Immunology

Volumn 10, Issue 1, 2014, Pages 31-39

  Cutolo, Maurizio ^a   Sulli, Alberto ^a   Straub, Rainer H ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

cancer; chronic autoimmune diseases; circadian rhythms; endocrine immune system; estrogens; rheumatoid arthritis

Indexed keywords

ESTROGEN; GROWTH FACTOR; MONOCLONAL ANTIBODY;

ANGIOGENESIS; ANTIPROLIFERATIVE ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER GROWTH; CELL PROLIFERATION; CHRONIC INFLAMMATION; ENDOCRINE SYSTEM; ESTROGEN BLOOD LEVEL; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; INFLAMMATORY DISEASE; METABOLITE; NEOPLASM; ONCOLOGY; PREGNANCY; REVIEW; RHEUMATIC DISEASE; RISK FACTOR; SEX; TISSUE INJURY; TISSUE REPAIR;

AGING; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CHRONIC DISEASE; ESTROGENS; FEMALE; HUMANS; INFLAMMATION; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SEX CHARACTERISTICS;

EID: 84893087604     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.863149     Document Type: Review

References (68)

1. Straub RH, Bijlsma JW, Masi A, Cutolo M. Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases - the 10-year update. Semin. Arthritis Rheum. doi:10.1016/j. semarthrit.2013.04.008 (2013) (Epub ahead of print).
2. Cutolo M, Sulli A, Seriolo B, Accardo S, Masi AT. Estrogens, the immune response and autoimmunity. Clin. Exp. Rheumatol. 13, 217-226 (1995).
3. Lockshin MD. Sex ratio and rheumatic disease. Autoimmun. Rev. 1, 162-167 (2002).
4. Kvien TK, Uhlig T, Ødegard S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann. NY Acad. Sci. 1069, 212-222 (2006).
5. Cutolo M, Capellino S, Straub RH. Oestrogens in rheumatic diseases: friend or foe? Rheumatology (Oxford) 47(Suppl. 3), iii2-iii5 (2008).
6. Magalhaes R, Stiehl P, Morawietz L, Berek C, Krenn V. Morphological and molecular pathology of the B cell response in synovitis of rheumatoid arthritis. Virchows Arch. 441, 415-427 (2002).
7. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707-717 (2000).
8. Straub RH, Buttgereit F, Cutolo M. Benefit of pregnancy in inflammatory arthritis. Ann. Rheum. Dis. 64, 801-809 (2005).
9. Cutolo M, Brizzolara R, Atzeni F, Capellino S, Straub RH, Puttini PC. The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases. Ann. NY Acad. Sci. 1193, 36-42 (2010).
10. Straub RH. The complex role of estrogens in inflammation. Endocr. Rev. 28, 521-574 (2007).
11. Hansar Ahmed S, Hissong BD, Verthelyi K, Donner K, Becker K, Karpuzoglu-Sahin E. Gender and autoimmune diseases: possible role of estrogenic compounds Environ. Health Perspect. 107, 681-687 (1999).
12. Cutolo M, Sulli A, Straub RH. Estrogen metabolism and autoimmunity. Autoimmun. Rev. 11, A460-A464 (2012).
13. Villaggio B, Soldano S, Cutolo M. 1,25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages. Clin. Exp. Rheumatol. 30, 934-938 (2012).
14. Cutolo M. The challenges of using vitamin D in cancer prevention and prognosis. Isr. Med. Assoc. J. 14, 637-639 (2012).
15. Castagnetta LA, Carruba G, Granata OM et al. Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J. Rheumatol. 30, 2597-2605 (2003).
16. Villaggio B, Soldano S, Cutolo M. 1,25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages. Clin. Exp. Rheumatol. 30, 934-938 (2012).
17. Amaral C, Varela C, Borges M et al. Steroidal aromatase inhibitors inhibit growth of hormone-dependent breast cancer cells by inducing cell cycle arrest and apoptosis. Apoptosis 18(11), 1426-1436 (2013).
18. Weidler C, Harle P, Schedel J, Schmidt M, Scho?lmerich J, Straub RH. Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J. Rheumatol. 3, 489-494 (2004).
19. Li KM, Todorovic R, Devanesan P et al. Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. Carcinogenesis 25, 289-297 (2004).
20. Dubey RK, Tyurina YY, Tyurin VA et al. Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. Circ. Res. 84, 229-239 (1999).
21. Schmidt M, Hartung R, Capellino S, Cutolo M, Pfeifer-Leeg A, Straub RH. Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in synovial cells of patients with rheumatoid arthritis and patients with osteoarthritis. Arthritis Rheum. 60, 2913-2922 (2009).
22. Folomeev M, Dougados M, Beaune J et al. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus 1(3), 191-195 (1992).
23. Kramer PR, Kramer SF, Guan G. beta-estradiol regulates cytokine release through modulation of CD16 expression in monocytes and monocyte-derived macrophages. Arthritis Rheum. 50, 1967-1975 (2004).
24. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum. 22, 1195-1198 (1979).
25. Rakoff-Nahoum S. Why cancer and inflammation? Yale J. Biol. Med. 79, 123-130 (2006).
26. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357(9255), 539-545 (2001).
27. Khan WA, Moinuddin, Habib S. Preferential recognition of catechol-estrogen modified DNA by circulating autoantibodies in cancer patients. Biochimie 95, 329-335 (2013).
28. Khan WA, Habib S, Khan WA, Alam K, Moinuddin. Enhanced binding of circulating SLE autoantibodies to catecholestrogen-copper-modified DNA. Mol. Cell Biochem. 315, 143-150 (2008).
29. Khan WA, Uddin M, Khan MW, Chabbra HS. Catecholoestrogens: possible role in systemic lupus erythematosus. Rheumatology (Oxford) 48, 1345-1351 (2009).
30. Khan WA, Moinuddin, Assiri AS. Immunochemical studies on catechol-estrogen modified plasmid: possible role in rheumatoid arthritis. J. Clin. Immunol. 31, 22-29 (2011).
31. Ostensen M, Brucato A, Carp H et al. Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology (Oxford) 50, 657-664 (2011).
32. Doria A, Iaccarino L, Sarzi-Puttini P et al. Pregnancy and systemic lupus erythematosus. Ann. NY Acad. Sci. 1069, 247-256 (2006).
33. Carvalheiras G, Vita P, Marta S et al. Pregnancy and systemic lupus erythematosus: review of clinical features and outcome of 51 pregnancies at a single institution. Clin. Rev. Allergy Immunol. 38, 302-306 (2010).
34. Doria A, Cutolo M, Ghirardello A et al. Effect of pregnancy on serum cytokines in SLE patients. Arthritis Res. Ther. 1, R66 (2012).
35. Taraborelli M, Ramoni V, Brucato A et al. Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. Arthritis Rheum. 64, 1970-1977 (2012).
36. Soldano S, Montagna P, Brizzolara R et al. Effects of estrogens on extracellular matrix synthesis in cultures of human normal and scleroderma skin fibroblasts. Ann. NY Acad. Sci. 1193, 25-29 (2010).
37. Soldano S, Montagna P, Villaggio B et al. Endothelin and sex hormones modulate the fibronectin synthesis by cultured human skin scleroderma fibroblasts. Ann. Rheum. Dis. 68, 599-602 (2009).
38. Aida-Yasuoka K, Peoples C, Yasuoka H et al. Estradiol promotes the development of a fibrotic phenotype and is increased in the serum of patients with systemic sclerosis. Ann. Rheum. Dis. 15(1), R10 (2009).
39. Cutolo M, Montagna P, Brizzolara R et al. Sex hormones modulate the effects of Leflunomide on cytokine production by cultures of differentiated monocyte/ macrophages and synovial macrophages from rheumatoid arthritis patients. J. Autoimmun. 32, 254-260 (2009).
40. Dziedziejko V, Kurzawski M, Safranow K, Chlubek D, Pawlik A. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 12(1), 41-47 (2011
41. Montagna P, Brizzolara R, Soldano S, Pizzorni C, Sulli A, Cutolo M. Sex hormones and leflunomide treatment of human macrophage cultures: effects on apoptosis. Int. J. Clin. Exp. Med. 2, 221-232 (2009).
42. Montagna P, Soldano S, Brizzolara R et al. Estrogens interfere with leflunomide modulation of cytokine production by human activated monocytes. Ann. NY Acad. Sci. 1193, 30-35 (2010).
43. Mufudza C, Sorofa W, Chiyaka ET. Assessing the effects of estrogen on the dynamics of breast cancer. Comput. Math. Methods Med. 2012, 473572 (2012).
44. Dossus L, Lukanova A, Rinaldi S, Allen N, Cust AE, Becker S. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort-a factor analysis. Am. J. Epidemiol. 177, 787-799 (2013).
45. Dai R, Phillips RA, Zhang Y, Khan D, Crasta O, Ahmed SA. Suppression of LPS-induced Interferon-gamma and nitric oxide in splenic lymphocytes by select estrogen-regulated microRNAs: a novel mechanism of immune modulation. Blood 112, 4591-4597 (2008).
46. Miao CG, Yang YY, He X et al. The emerging role of microRNAs in the pathogenesis of systemic lupus erythematosus. Cell Signal. 25, 1828-1836 (2013).
47. Di Leva G, Piovan C, Gasparini P et al. Estrogen mediated-activation of miR-191/cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet. 9, e1003311 (2013).
48. Duncan GS, Brenner D, Tusche MW, Bru?stle A, Knobbe CB, Elia AJ et al. 2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation. Proc. Natl Acad. Sci. USA 109, 21034-21039 (2012).
49. Cutolo M. Hormone therapy in rheumatic diseases. Curr. Opin. Rheumatol. 22, 257-263 (2010).
50. Cutolo M. Androgens in rheumatoid arthritis: when are they effectors? Arthritis Res. Ther. 11(5), 126-131 (2009).
51. Cutolo M, Balleari E, Giusti M, Intra E, Accardo S. Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum. 34, 1-5 (1991).
52. Cutolo M. Sex hormone adjuvant therapy in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 26, 881-895 (2000).
53. Ho SM, Lee MT, Lam HM, Leung YK. Estrogens and prostate cancer: etiology, mediators, prevention, and management. Endocrinol. Metab. Clin. North Am. 40, 591-614 (2011).
54. Lanzino M, Maris P, Sirianni R et al. DAX- 1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation. Cell Death Dis. 4, e724-e730 (2013).
55. Kawashima H, Nakatani T. Involvement of estrogen receptors in prostatic diseases. Int. J. Urol. 19, 512-522 (2012).
56. Dayan M, Zinger H, Kalush F et al. The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations. Immunology 90, 101-108 (1997).
57. Sthoeger ZM, Bentwich Z, Zinger H, Mozes E. The beneficial effect of the estrogen antagonist, tamoxifen, on experimental systemic lupus erythematosus. J. Rheumatol. 21, 2231-2238 (1994).
58. Chighizola C, Meroni PL. The role of environmental estrogens and autoimmunity. Autoimmun. Rev. 11, A493-A501 (2012).
59. Zandman-Goddard G, Solomon M, Rosman Z, Peeva E, Shoenfeld Y. Environment and lupus-related diseases. Lupus 21, 241-250 (2012).
60. Sherlock JP, Filer AD, Isaacs JD, Buckley CD. What can rheumatologists learn from translational cancer therapy? Arthritis Res. Ther. 15, 114-118 (2013).
61. Cutolo M. Chronobiology and the treatment of rheumatoid arthritis. Curr. Opin. Rheumatol. 24, 312-318 (2012).
62. Cutolo M, Straub RH. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun. Rev. 7, 223-228 (2008).
63. To H, Yoshimatsu H, Tomonari M et al. Methotrexate chronotherapy is effective against rheumatoid arthritis. Chronobiol. Int. 28, 267-274 (2011).
64. Cutolo M, Straub RH, Buttgereit F. Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside. Ann. Rheum. Dis. 67, 905-908 (2008).
65. Cutolo M. Rheumatoid. arthritis: circadian and circannual rhythms in RA. Nature Rev. Rheumatol. 7, 500-502 (2011).
66. Mazzoccoli G, Sothern RB, Francavilla M et al. Hormone and cytokine circadian alteration in non-small cell lung cancer patients. Int. J. Immunopathol. Pharmacol. 25, 691-702 (2012).
67. Rossetti S, Corlazzoli F, Gregorski A, Azmi NH, Sacchi N. Identification of an estrogen-regulated circadian mechanism necessary for breast acinar morphogenesis. Cell Cycle 11, 3691-3700 (2012).
68. Schmidt M, Weidler C, Naumann H, Anders S, Scho?lmerich J, Straub RH. Androgen conversion in osteoarthritis and rheumatoid arthritis synoviocytes - androstenedione and testosterone inhibit estrogen formation and favor production of more potent 5alpha-reduced androgens. Arthritis Res. Ther. 7, R938-R948 (2005).